RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > Quality & Compliance: Characterization of Risks, Research Subjects and the Regulatory Professional

Quality & Compliance: Characterization of Risks, Research Subjects and the Regulatory Professional

Posted 01 June 2008

The first article in this series1 examined the EMEA guideline2 issued following the injury of healthy volunteers in the TeGenero first-in-man clinical trial, while the second article3 explored some of the lessons learned from the study. Part three explores the concept of risk as it relates to research subjects. This article looks at the roles of the research subject and the regulatory professional in first-inman phase 1 studies for novel compounds and those that could be classified as relatively high risk.

 

© 2022 Regulatory Affairs Professionals Society.